Insulet Corporation Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
We view Insulet as a widely held public medical device company navigating a genuinely consequential quality and governance test, with no founder or controlling shareholder shaping strategy since new Chief Executive Officer Ashley McEvoy took over in April 2025 amid strong underlying commercial momentum. In our assessment, the company's tenth consecutive year of 20 percent or greater constant currency revenue growth in fiscal 2025 demonstrates that the core Omnipod 5 automated insulin delivery franchise remains genuinely differentiated in the marketplace, even as the company simultaneously manages a Class I recall over a cannula defect affecting certain Omnipod and Omnipod 5 pods. We think the July 2026 securities class action, alleging that Insulet and its executives made misleading statements about manufacturing controls and procedures, represents a serious governance and disclosure question that dispersed institutional shareholders will likely scrutinize closely as the litigation proceeds toward the August 2026 lead plaintiff deadline. We calculate that the leadership transition to Ashley McEvoy, occurring roughly a year before the recall was classified as Class I, positions the new chief executive to address manufacturing quality concerns without being personally implicated in whatever statements preceded the disclosed issues. We believe the company's decision to temper 2026 guidance due to higher customer attrition in the type 2 diabetes segment, disclosed alongside continued double digit growth guidance for the broader business, reflects a management team attempting to set realistic expectations during a period of heightened scrutiny rather than overpromising recovery. In our view, the combination of strong core commercial performance and serious manufacturing quality and litigation risk creates a genuinely bifurcated picture for Insulet that dispersed institutional shareholders will need to weigh carefully. For Insulet shareholders, we think the central ownership question going forward is whether the board's oversight of the recall remediation and litigation defense proves adequate to preserve the underlying commercial strength of the Omnipod 5 franchise.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Vanguard Group's combined roughly 11.5 percent position across its fund entities edges out BlackRock's roughly 9.65 percent stake as Insulet's largest institutional holding, with State Street, AQR Capital, Baillie Gifford, Geode Capital, Two Sigma, T. Rowe Price, and Invesco rounding out a genuinely dispersed shareholder base typical of a large cap medical device company. We think the ongoing securities class action, filed in July 2026 and alleging misleading statements about manufacturing controls tied to the Class I recall, represents the kind of governance and disclosure dispute that institutional shareholders in aggregate, rather than any single dominant holder, will ultimately need to resolve through litigation outcomes and continued proxy engagement. In our assessment, the involvement of multiple plaintiff-side securities litigation firms issuing investor alerts through August 2026 suggests meaningful institutional shareholder interest in pursuing accountability for the alleged manufacturing disclosure failures, even though no single large holder appears to be driving this response. We calculate that the leadership transition to Ashley McEvoy in April 2025, occurring before the recall was classified as Class I, likely gives institutional shareholders some confidence that new leadership can address the underlying manufacturing quality issues without the complication of defending decisions made under the prior chief executive's tenure. We believe continued strong institutional ownership through this period of litigation and recall remediation reflects underlying confidence in the Omnipod 5 franchise's commercial trajectory, even as shareholders simultaneously pursue accountability for the specific manufacturing disclosure allegations. For Insulet shareholders, we think this dispersed ownership structure means the litigation outcome and recall remediation progress will likely be the primary drivers of near term shareholder sentiment rather than any negotiation with a concentrated holder.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Omnipod 5 | Brand | Automated insulin delivery system integrating continuous glucose monitor data, the company's flagship product |
| Omnipod DASH | Brand | Tubeless insulin pump system with a separate handheld controller device |
| Omnipod GO | Brand | Basal-only, non-adjustable insulin pod designed for adults with type 2 diabetes |
Portfolio Analysis
Omnipod 5 stands as Insulet's flagship brand and primary growth driver, the first tubeless automated insulin delivery system on the market, integrating continuous glucose monitor data to automatically adjust insulin dosing for patients with diabetes. We think the company's decision to maintain a focused three-product brand architecture, spanning Omnipod 5, the smartphone-compatible Omnipod DASH, and the basal-only Omnipod GO designed for type 2 diabetes patients, reflects a deliberate strategy of serving distinct patient segments within diabetes management rather than pursuing unrelated product diversification. In our assessment, the Class I recall affecting certain Omnipod and Omnipod 5 pods over a cannula defect represents a genuinely serious threat to the brand's reputation for reliability, since insulin delivery devices carry life-critical safety requirements that a manufacturing defect directly implicates. We believe the accompanying securities litigation, alleging misleading statements about manufacturing controls, compounds this brand risk by raising questions about whether quality issues were adequately disclosed to patients, physicians, and investors before the recall was classified as Class I. For Insulet shareholders, we think the practical brand question going forward is whether new Chief Executive Officer Ashley McEvoy can successfully rebuild confidence in the Omnipod brand's manufacturing reliability while the underlying automated insulin delivery technology continues to demonstrate strong clinical and commercial differentiation.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Tandem Diabetes Care | N/A | $1.02B FY2025 | Direct competitor in tubed insulin pump systems, most notably the t |
| Medtronic plc | N/A | $33.50B FY2025 | Diversified medical device company whose MiniMed diabetes division competes directly in insulin pump and automated delivery systems |
| Dexcom Inc. | N/A | $4.60B FY2025 | Continuous glucose monitoring company whose sensors integrate with Omnipod 5, functioning as both a complementary partner and a potential competitive threat if it expands into pump delivery |
| Insulet Corporation ★ | N/A | $2.70B FY2025 | Billerica, Massachusetts based maker of the tubeless Omnipod insulin delivery system |
Competitive Analysis
Medtronic plc, with roughly $33.50 billion in fiscal 2025 revenue, represents Insulet's largest and most diversified competitor, with its MiniMed diabetes division competing directly in insulin pump and automated delivery systems while benefiting from substantially greater scale and resources than Insulet can bring to bear. We think Tandem Diabetes Care poses the more direct competitive threat specifically within tubed insulin pump systems, with its t:slim X2 platform competing head to head with Omnipod 5 for the same automated insulin delivery patient population, at a considerably smaller scale of roughly $1.02 billion in fiscal 2025 revenue. In our assessment, Dexcom Inc., whose continuous glucose monitoring sensors integrate directly with Omnipod 5, occupies a genuinely complex position as both a critical technology partner and a potential future competitive threat should it expand into insulin delivery, a dynamic worth monitoring closely given how central Dexcom's sensor accuracy is to Omnipod 5's automated dosing algorithm. We calculate that Insulet's current Class I recall and securities litigation create a meaningful near term competitive opening for both Medtronic plc and Tandem Diabetes Care, since institutions and patients reassessing insulin delivery vendor relationships amid manufacturing quality concerns would naturally consider these established alternatives. We believe Insulet's tenth consecutive year of 20 percent or greater constant currency revenue growth, even amid these challenges, suggests the company retains meaningful competitive differentiation in tubeless pump design that neither Medtronic's MiniMed division nor Tandem Diabetes Care's tubed systems fully replicate. For Insulet shareholders, we think the central competitive question is whether the current recall and litigation meaningfully erode the company's historically strong competitive position, or whether its underlying technology advantages prove durable enough to weather this period of manufacturing scrutiny.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| N/A | — | — |
Acquisitions Analysis
Insulet has pursued essentially no acquisition activity throughout its history, instead growing entirely through internal development of its Omnipod insulin delivery platform since the company's 2000 founding, with its most notable inorganic investment being the 2013 acquisition of manufacturing capacity in Acton, Massachusetts rather than a business combination. We think this organic growth strategy, progressing from the original Omnipod system through Omnipod DASH to the automated insulin delivery capabilities of Omnipod 5, reflects a company that found sufficient competitive advantage in its core tubeless pump technology without needing to acquire complementary capabilities. In our assessment, the absence of acquisition activity also means Insulet's current manufacturing quality challenges, evidenced by the Class I recall affecting certain Omnipod and Omnipod 5 pods, cannot be attributed to integration issues from an acquired business, instead pointing directly to the company's own core manufacturing operations. We calculate that Insulet's singular focus on organic Omnipod platform development has concentrated both its commercial success and its current manufacturing risk within a single product architecture, a meaningfully different risk profile than a more diversified medical device competitor with multiple acquired product lines would carry. We believe the company's continued double digit revenue growth guidance for 2026, even amid the recall and litigation, suggests underlying confidence that the manufacturing issues are addressable without requiring an acquisition of external manufacturing expertise or capacity. For Insulet shareholders, we think the key forward looking question is whether the current manufacturing quality challenges might eventually prompt the company to consider acquiring specialized quality systems or manufacturing capabilities, a meaningful departure from its historical organic growth approach.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Insulet has no history of mergers, spinoffs, or major acquisitions since its 2000 founding, having built its entire business organically on the development and commercialization of its tubeless Omnipod insulin delivery platform through its 2007 initial public offering and beyond. We think this history of structural simplicity, a single company pursuing a single core technology platform without the complexity of integrating acquired businesses, distinguishes Insulet from many medical device peers that have grown substantially through corporate combination. In our assessment, the absence of acquisition activity means the company's current Class I recall and manufacturing quality challenges reflect issues within its own longstanding manufacturing operations rather than problems inherited from an acquired business, a distinction that places full accountability for remediation squarely on Insulet's existing management and board. We believe the April 2025 leadership transition to Ashley McEvoy, occurring within this otherwise structurally stable company, represents the most significant recent organizational change, bringing new executive oversight to bear on the manufacturing quality issues that would be disclosed as a Class I recall roughly a year later. For Insulet shareholders, we think this history of structural continuity, absent any merger or spinoff complexity, means the current recall and litigation can be evaluated as a direct reflection of the company's own operational execution rather than as an integration or legacy issue from a prior corporate transaction.
Ownership History
Ownership History Analysis
Insulet began in 2000 with a focused mission to develop a tubeless insulin pump system, launching its first Omnipod system in 2005 and completing its initial public offering in 2007, building over more than two decades into a company defined almost entirely by continuous iteration on its core insulin delivery platform. We think the progression from the original Omnipod through Omnipod DASH's smartphone-compatible controller to Omnipod 5's automated insulin delivery capabilities in 2022 represents one of the more successful examples of sustained organic product innovation among the medical device companies we track, culminating in ten consecutive years of 20 percent or greater constant currency revenue growth through fiscal 2025. The 2025 to 2026 period brought the company's most significant recent challenges, encompassing the April 2025 leadership transition to Ashley McEvoy, a Class I recall affecting certain Omnipod and Omnipod 5 pods over a cannula defect, and a July 2026 securities class action alleging misleading statements about manufacturing controls. We believe this recent stretch represents a genuine test of the operational foundation built over more than two decades of organic growth, testing whether the company's manufacturing quality systems can match the commercial success of its underlying insulin delivery technology. For Insulet shareholders, the arc from a 2000 founding through more than two decades of sustained Omnipod platform innovation to a 2025-2026 period of manufacturing quality reckoning illustrates how even a company with a genuinely differentiated core technology must continuously invest in the operational discipline needed to support it at scale.
Ownership Explained
Insulet is a widely held public medical device company with no founder or controlling shareholder, trading on Nasdaq under ticker PODD since building its entire business on the tubeless Omnipod insulin delivery platform. Vanguard Group holds the largest combined institutional position at roughly 11.5 percent across its fund entities, followed by BlackRock near 9.65 percent and State Street near 4.61 percent. The company reported fiscal 2025 revenue of roughly $2.7 billion, marking a tenth consecutive year of 20 percent or greater constant currency growth, under new President and Chief Executive Officer Ashley McEvoy, who succeeded Jim Hollingshead in April 2025. The company is currently navigating a Class I recall affecting certain Omnipod and Omnipod 5 pods tied to a cannula defect, alongside a securities class action filed in July 2026 alleging misleading statements about manufacturing controls, even as its core Omnipod 5 automated insulin delivery platform continues to drive strong commercial growth.
Because Insulet has no controlling shareholder, its response to the current Class I recall and accompanying securities litigation runs through an independent board accountable to a broad institutional shareholder base rather than to a founder with personal reputational stakes in the outcome. For patients and physicians who depend on the Omnipod platform for daily diabetes management, this structure means recall remediation and quality system improvements reflect board level accountability decisions rather than any single investor's preference, though the ongoing litigation suggests some institutional shareholders believe communication about manufacturing risks fell short of expectations. We think the dispersed ownership also means new Chief Executive Officer Ashley McEvoy has a genuine mandate to address both the recall and underlying manufacturing quality concerns without the complication of a founder or controlling holder resistant to operational change.